Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

Related Insights

New McKinsey research reveals a significant AI adoption gap. While 88% of organizations use AI, nearly two-thirds haven't scaled it beyond pilots, meaning they are not behind their peers. This explains why only 39% report enterprise-level EBIT impact. True high-performers succeed by fundamentally redesigning workflows, not just experimenting.

A significant implementation roadblock is the ownership battle between IT and business functions. IT wants to control infrastructure and moves slowly, taking years. In response, business units run their own unsanctioned initiatives to move quickly, leading to a disconnected and unscalable approach to AI.

Companies struggle with AI not because of the models, but because their data is siloed. Adopting an 'integration-first' mindset is crucial for creating the unified data foundation AI requires.

Many firms are stuck in "pilot purgatory," launching numerous small, siloed AI tests. While individually successful, these experiments fail to integrate into the broader business system, creating an illusion of progress without delivering strategic, enterprise-level value.

Many pharma companies have breakthrough AI results in isolated functions, or "pockets of excellence." However, the ultimate competitive advantage will go to the company that first connects these disparate successes into a single, integrated, enterprise-wide AI capability, thereby creating compounded value across the organization.

Many pharma companies allow various departments to run numerous, disconnected AI pilots without a central strategy. This lack of strategic alignment means most pilots fail to move beyond the proof-of-concept stage, with 85% yielding no measurable return on investment.

Successful AI strategy development begins by asking executives about their primary business challenges, such as R&D costs or time-to-market. Only after identifying these core problems should AI solutions be mapped to them. This ensures AI initiatives are directly tied to tangible value creation.

Companies struggle to get value from AI because their data is fragmented across different systems (ERP, CRM, finance) with poor integrity. The primary challenge isn't the AI models themselves, but integrating these disparate data sets into a unified platform that agents can act upon.

Much like the big data and cloud eras, a high percentage of enterprise AI projects are failing to move beyond the MVP stage. Companies are investing heavily without a clear strategy for implementation and ROI, leading to a "rush off a cliff" mentality and repeated historical mistakes.

McKinsey finds over half the challenge in leveraging AI is organizational, not technical. To see enterprise-level value, companies must flatten hierarchies, break down departmental silos, and redesign workflows, a process that is proving harder and longer than leaders expect.

Pharma's AI Failures Stem from Strategic Fragmentation, Not Technical Shortcomings | RiffOn